Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution.
D000328:Adult; D001249:Asthma / Q000503:physiopathology; D001548:Benzalkonium Compounds / Q000009:adverse effects*; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D003251:Constriction, Pathologic / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000009:adverse effects*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects; D008297:Male; D009330:Nebulizers and Vaporizers; D010592:Pharmaceutic Aids / Q000009:adverse effects*; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects*; D012996:Solutions
D001548:Benzalkonium Compounds; D010592:Pharmaceutic Aids; D011310:Preservatives, Pharmaceutical; D012996:Solutions; D004492:Edetic Acid; D009241:Ipratropium